# Selank and DSIP FAQ — Peptivio Peptides

> Frequently asked questions about Selank and DSIP — two Cognitive & Nootropic research peptides studied for mood, stress and sleep — answered from the peer-reviewed literature, with citations.

Direct, citation-anchored answers to the questions most often asked about Selank and DSIP — the anxiolytic and sleep peptides in the nootropic research space.

## What is Selank?

Selank is a synthetic heptapeptide (seven amino acids, sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro) designed as a metabolically stable analogue of tuftsin, an endogenous immunomodulatory tetrapeptide derived from immunoglobulin G. The C-terminal Pro-Gly-Pro extension slows enzymatic breakdown and is responsible for Selank also being called **TP-7** or tuftsin analogue TP-7. It is distinct from Semax, which is a different compound with a different sequence and mechanism. Selank is not approved by the FDA; its regulatory registration as an anxiolytic exists only in Russia, and it is sold as a research chemical elsewhere [1][6].

## What does Selank do?

In preclinical models and limited Russian clinical trials, Selank produced anxiolytic effects without sedation, cognitive impairment, or the withdrawal and dependence associated with benzodiazepines [6]. It modulates the brain's inhibitory GABA system as a positive allosteric modulator of GABA receptor binding [1], shifts expression of GABAergic-pathway genes in the frontal cortex [3], and inhibits enkephalin-degrading enzymes — potentially extending the life of the body's own anxiety-buffering enkephalins [7]. It also modulated BDNF expression in rat hippocampus and shifted cytokine balance in patients with anxiety-asthenic disorders [4][5]. These are research findings, not a summary of approved clinical uses.

## What is Selank peptide used for in research?

In research, Selank has been studied primarily for anxiolytic activity — reducing anxiety without sedation — in animal stress models and in small Russian clinical studies involving patients with generalized anxiety disorder and related conditions [6]. Preclinical work has also examined its effects on BDNF expression and neuroplasticity [4], its interaction with the GABAergic and enkephalinergic systems [1][7], and its immunomodulatory properties derived from its tuftsin ancestry [5]. It is studied as a research tool; this desk makes no claim about its use as a treatment for any condition in any human population.

## How does Selank work?

The two best-supported proposed mechanisms are: (1) **positive allosteric modulation of GABA receptors** — it enhances GABA receptor binding in a concentration-dependent, subtype-selective way distinct from benzodiazepines, and shifts GABAergic gene expression in the frontal cortex [1][3]; and (2) **inhibition of enkephalin-degrading enzymes** — dose-dependently slowing the breakdown of endogenous enkephalins in human plasma in vitro, potentially stabilizing the body's own opioid-adjacent anxiety-buffering system [7]. Additional targets include BDNF upregulation in the hippocampus [4] and Th1/Th2 cytokine modulation [5]. These are proposed mechanisms supported by preclinical and in-vitro evidence; a complete, validated human mechanistic account has not been established.

## What is DSIP peptide?

DSIP (Delta Sleep-Inducing Peptide, INN: emideltide) is an endogenous nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, first isolated from cerebral venous blood of sleeping rabbits by Schoenenberger and Monnier. It occurs naturally in the human hypothalamus, limbic system, pituitary, and peripheral tissues. Its name comes from its reported ability to promote slow-wave (delta) EEG activity when infused into the brains of recipient rabbits. Despite more than forty years of research, no DSIP receptor, gene, or biosynthetic precursor has been identified [9]. No emideltide product has ever been approved as a drug by any regulator.

## What is DSIP peptide used for in research?

DSIP has been studied for its potential to promote slow-wave sleep, modulate the stress-hormone (HPA) axis — including a significant reduction in ACTH-like immunoreactivity in men after intravenous administration [11] — and as an adjunct in anesthesia and pain pilot work. Mouse lifespan and tumor-incidence research with a DSIP-containing preparation (Deltaran) showed striking geroprotective signals, though this comes from a limited set of Russian research groups and requires independent replication [10]. In 2024, a modified DSIP fusion peptide showed sleep-promoting and anxiolytic effects in an insomnia mouse model — though native DSIP was less effective in the same study [8]. Its overall research role is better described as "interesting but unresolved" than as "established" in any of these areas.

## What are the benefits of DSIP peptide?

The peer-reviewed literature contains modest, inconsistently reproduced signals: a small 1981 insomnia pilot found longer sleep, fewer interruptions, slightly more REM sleep, and no daytime sedation in six people given intravenous DSIP [12]; and a 1989 human study found it significantly lowered plasma ACTH for at least three hours [11]. In a 2024 mouse study, a modified fusion version reduced wakefulness and improved sleep architecture [8]. Community accounts among those who respond (roughly half, per informal estimates) describe falling asleep more easily and waking clear-headed. All of this is research observation and anecdote. **A large share of users report no benefit at all.** The 2006 *Journal of Neurochemistry* review concluded the sleep-inducing evidence is "extremely poorly documented and still weak" [9]. Benefits should be framed as hypothesis, not established effect.

## Does DSIP really work?

That question has a genuinely uncertain answer. The original observation that prompted its name has not been consistently reproduced in four decades of follow-up research, the mechanism is unknown, and a 2006 landmark review explicitly characterized the evidence as weak [9]. In the one small controlled human insomnia study, results were modest and the study has not been replicated in a modern trial [12]. Community experience is split: roughly half of users report a meaningful effect on sleep quality, and roughly half report nothing. The effect, when it appears, is described as a gentle nudge rather than a reliable sedative action. So "does it work" depends on what "work" means and for whom — and the honest answer is that no one knows why it works when it does, or why it fails so often when it doesn't [9].

## Is Selank safe?

Human safety data for Selank are limited to small Russian clinical studies spanning a few weeks, without long-term follow-up or Western replication. Within those studies it was well tolerated, without sedation, cognitive impairment, or withdrawal effects [6]. However: short-term tolerability in small, single-region trials is not long-term safety clearance. Selank outside Russia is sold as an unregulated research chemical with no pharmaceutical purity or identity guarantee. Its activity across GABA, opioid, serotonergic, dopaminergic, and immune pathways creates a real and essentially unstudied potential for drug interactions. There are no human data for pregnancy, breastfeeding, or significant medical conditions. Nothing in this answer constitutes medical advice [1][6][7][5].

## Is Selank the same as Semax?

No. Selank and Semax are two distinct synthetic research peptides that share Russian origin and appear together in nootropic communities, which is the source of frequent confusion — but they are not the same compound and have different sequences, origins, and proposed mechanisms. Selank (TP-7) is a tuftsin analogue: Thr-Lys-Pro-Arg-Pro-Gly-Pro, derived from an IgG-heavy-chain peptide, studied for anxiolytic activity via GABAergic and enkephalinase mechanisms. Semax is an ACTH(4-7) analogue derived from a fragment of adrenocorticotropin, studied primarily for neuroprotection and cognitive enhancement via BDNF and neurotrophin pathways. They are different molecules studied for partially different purposes. This desk covers only Selank.

## Can DSIP be combined with other sleep aids?

This question cannot be answered from the available evidence, and that is itself an important answer. Because no DSIP receptor or mechanism has been identified, there is no rational pharmacological basis for predicting how it interacts with other agents that affect the central nervous system [9]. DSIP has been studied as an adjunct in anesthesia contexts and was proposed in withdrawal pilot work to interact with the endogenous opioid system, suggesting CNS activity is plausible even if undefined. Stacking an agent with an unknown mechanism on top of sedating substances — whether prescription hypnotics, benzodiazepines, or alcohol — has never been tested in a controlled study. There is no reported harm, but the absence of reported harm in tiny old pilot data is not evidence of safety in combination. This is not medical advice.

## Are there any side effects of Selank or DSIP?

Based on the literature and community reports (anecdotal, not clinical evidence): Selank's most common reported side effects are mild nasal irritation with intranasal use, occasional headache, and in a minority, mild over-calm, drowsiness, or slight mental detachment, especially with more frequent use. Community accounts also consistently describe an apparent absence of dependence or rebound anxiety, though this is anecdotal and does not constitute a long-term safety record. For DSIP, the most commonly reported side effect in both community accounts and older clinical reports is headache, described as usually mild and transient. A minority report next-day grogginess, mild nausea, dizziness, or lightheadedness. Some describe unpredictable timing — sedation arriving at the wrong hour. Both compounds are sold as unregulated research chemicals with no pharmaceutical quality guarantee; product-specific risks exist independent of any peptide pharmacology [6][9][12].

---

An independent literature digest — curious, citation-grounded, and honest about what the research does and does not establish.